POZEN Announces U.S. Rights for VIMOVO® to Be Acquired by Horizon Pharma USA, Inc.

  POZEN Announces U.S. Rights for VIMOVO® to Be Acquired by Horizon Pharma
  USA, Inc.

     Guaranteed Minimum Royalty Payments to POZEN Key Element of New Deal

Business Wire

CHAPEL HILL, N.C. -- November 19, 2013

POZEN Inc. (NASDAQ: POZN),  a pharmaceutical company committed to transforming
medicine that transforms lives, today announced that AstraZeneca AB and
Horizon Pharma USA, Inc. (NASDAQ: HZNP) have entered into an agreement for
Horizon to acquire the U.S. rights for VIMOVO^® (naproxen / esomeprazole
magnesium) delayed release tablets. Under the terms of the agreement, POZEN
will continue to receive a 10% royalty on Net Sales of products sold in the
United States, with guaranteed annual minimum royalty payments of $5 million
in 2014, and $7.5 million each year thereafter, provided that the patents
owned by POZEN which cover VIMOVO^® are in effect and no generic forms of
VIMOVO^® are on the market. Also under the agreement, Horizon has assumed
AstraZeneca’s right to lead the on-going Paragraph IV litigation for VIMOVO^®
and will assume all patent-related defense costs relating to such litigation,
including reimbursement for a specified amount of the cost of counsel retained
by POZEN. AstraZeneca will continue to have rights to commercialize VIMOVO^®
outside of the United States.

“We are very pleased that Horizon will take over the sales and marketing of
VIMOVO^® in the United States,” said John R. Plachetka, Pharm.D., Chairman,
President and Chief Executive Officer of POZEN. “As evidenced by their
experience in the osteoarthritis market, we believe that the management team
and the employees of Horizon are uniquely qualified to significantly increase
sales of VIMOVO^®. We also extend our gratitude to AstraZeneca for their role
in making this transaction possible, and for their continuing efforts to
maximize the commercial potential of VIMOVO^® outside the U.S.”


POZEN will host a webcast to discuss the Horizon Pharma USA, Inc. agreement on
Tuesday, November 19, 2013 at 11:00 a.m. (ET). The webcast can be accessed
live and will be available for replay at www.pozen.com.


POZEN Inc. is a small pharmaceutical company that specializes in developing
novel therapeutics for unmet medical needs and licensing those products to
other pharmaceutical companies for commercialization. By utilizing a unique
in-source model and focusing on integrated therapies, POZEN has successfully
developed and obtained FDA approval of two self-invented products in two
years. Funded by these milestones/royalty streams, POZEN has created a
portfolio of cost-effective, evidence-based integrated aspirin therapies
designed to enable the full power of aspirin by reducing its GI damage.

POZEN is currently seeking strategic partners to help maximize the
opportunities for its portfolio assets.

The Company's common stock is traded under the symbol “POZN” on The NASDAQ
Global Market. For more detailed company information, including copies of this
and other press releases, please visit www.pozen.com.

About Horizon

Horizon Pharma, Inc. is a specialty pharmaceutical company that has developed
and is commercializing products to primary care, orthopedic surgeons and
rheumatologists. The Company markets DUEXIS^®, and RAYOS^®/LODOTRA^®, and will
market VIMOVO^®, which target unmet therapeutic needs in arthritis, pain and
inflammatory diseases. The Company's strategy is to develop, acquire,
in-license and/or co-promote additional innovative medicines where it can
execute a targeted commercial strategy in specific therapeutic areas while
taking advantage of its commercial strengths and the infrastructure the
Company has put in place. For more information, please visit

About VIMOVO^®

VIMOVO^® (naproxen / esomeprazole magnesium) is a fixed-dose combination of
delayed-release enteric-coated naproxen, a non-steroidal anti-inflammatory
drug (NSAID), and immediate-release esomeprazole, a stomach acid-reducing
proton pump inhibitor (PPI), approved for the relief of signs and symptoms of
osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to
decrease the risk of developing gastric ulcers in patients at risk of
developing NSAID-associated gastric ulcers. VIMOVO^® is not recommended for
use in children younger than 18 years of age. VIMOVO^® is not recommended for
initial treatment of acute pain because the absorption of naproxen is delayed
compared to absorption from other naproxen-containing products. Controlled
studies do not extend beyond six months. VIMOVO^® should be used at the lowest
dose and for the shortest amount of time as directed by your health care

For Full Prescribing Information see www.VIMOVO®.com.

Forward-Looking Statements

Statements included in this press release that are not historical in nature
are “forward-looking statements” within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995. You should
be aware that our actual results, our ability to return value to our
stockholders, including any cash distributions, and our future prospects could
differ materially from those contained in the forward-looking statements,
which are based on current market data and research (including third party and
POZEN sponsored market studies and reports), management’s current expectations
and are subject to a number of risks and uncertainties, including, but not
limited to, our inability to further license our PA product candidates on
terms and timing acceptable to us, our failure to successfully commercialize
our product candidates; costs and delays in the development and/or FDA
approval of our product candidates, including as a result of the need to
conduct additional studies, or the failure to obtain such approval of our
product candidates for all expected indications, including as a result of
changes in regulatory standards or the regulatory environment during the
development period of any of our product candidates; uncertainties in clinical
trial results or the timing of such trials, resulting in, among other things,
an extension in the period over which we recognize deferred revenue or our
failure to achieve milestones that would have provided us with revenue; our
inability to maintain or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements necessary for the
development, manufacture, commercialization, marketing, sales and distribution
of any products, including our dependence on AstraZeneca and Horizon Pharma
for the sales and marketing of VIMOVO^®, our dependence on Sanofi US for the
sales and marketing of PA8140/PA32540 in the United States, if approved, and
our dependence on Patheon for the manufacture of PA8140/PA32540; competitive
factors; our inability to protect our patents or proprietary rights and obtain
necessary rights to third party patents and intellectual property to operate
our business; our inability to operate our business without infringing the
patents and proprietary rights of others; general economic conditions; the
failure of any products to gain market acceptance; our inability to obtain any
additional required financing; technological changes; government regulation;
changes in industry practice; and one-time events, including those discussed
herein and in our Quarterly Report on Form 10-Q for the period ended September
30, 2013. We do not intend to update any of these factors or to publicly
announce the results of any revisions to these forward-looking statements.


Bill Hodges, Chief Financial Officer, 919-913-1030
Stephanie Bonestell, Manager, Investor Relations & Public Relations,
Press spacebar to pause and continue. Press esc to stop.